Companies › Noema Pharma
2 active drug programs in 2 registered trials: 2 Phase 2; Psychiatry, Neurology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Basimglurant (NOE-101) Metabotropic glutamate receptor 5 modulator | GRM5 | Phase 2 | Trigeminal Neuralgia | Feb 2027 |
| Gemlapodect (NOE-105) selective PDE10A inhibitor | PDE10A | Phase 2 | Tourette Syndrome | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06315751 | Gemlapodect (NOE-105) | Phase 2 | Tourette Syndrome | Psychiatry | Jun 2026 |
| NCT05217628 | Basimglurant (NOE-101) | Phase 2 | Trigeminal Neuralgia | Neurology | Feb 2027 |
–
Reunion Neuroscience TrueBinding Spinogenix Shanghai Auzone Biological Technology MapLight Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.